What do systematic reviews say?

Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone

• Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 3378 participants
  Moderate

Long‐acting beta2‐agonist plus tiotropium vs long‐acting beta2‐agonist alone

Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with long‐acting beta2‐agonist alone (moderate certainty).

• Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes only
  OR 1.53 [1.31, 1.79]
  2 studies · 2923 participants
  Moderate

Long‐acting beta2‐agonist plus tiotropium vs tiotropium

• Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 6709 participants
  Moderate

Long‐acting beta2‐agonist plus tiotropium vs tiotropium

Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with tiotropium alone (moderate certainty).

• Long‐acting beta₂‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta₂‐agonist alone for… 2015 · Cochrane Headline outcomes only
  OR 1.32 [1.19, 1.46]
  3 studies · 5978 participants
  Moderate